Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00884247
First received: April 17, 2009
Last updated: December 6, 2010
Last verified: December 2010
  Purpose

The study aims to evaluate if a GERD treatment programme, in accordance with current regional recommendations, in a company health care setting, has an impact on health related quality of life (HRQoL), symptoms, and productivity in GERD patients.


Condition
GERD

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective, Non Interventional Study to Evaluate the Effects on Quality of Life, Symptoms and Productivity in Patients With Gastroesophageal Reflux Disease (GERD) After 6 Weeks Structured Treatment in a Company Health Care Setting

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 36
Study Start Date: April 2009
Study Completion Date: June 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Company health care setting

Criteria

Inclusion Criteria:

  • Female and/or male aged > 18 years
  • Diagnosis of GERD confirmed
  • Prescription of GERD treatment or already receiving GERD treatment

Exclusion Criteria:

  • Any symptom suggesting a need for further investigation
  • Previous participation in the present study
  • Current participation in a clinical study or participation in a clinical study during the last 30 days
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00884247

Locations
Sweden
Research Site
Hälsocenter, Södertälje, Sweden
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Svante Sjöstedt, MD, PhD AstraZeneca Sweden
Principal Investigator: Dan Regberg, MD AstraZeneca Sweden
  More Information

No publications provided

Responsible Party: Svante Sjöstedt/MC MDOTA, AstraZeneca
ClinicalTrials.gov Identifier: NCT00884247     History of Changes
Other Study ID Numbers: NIS-GSE-DUM-2009/1
Study First Received: April 17, 2009
Last Updated: December 6, 2010
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by AstraZeneca:
GERD
Quality of life
Structured treatment

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on April 22, 2014